XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks
XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.